Can Avigan (Favipiravir) Prevent SARS-CoV-2 Infection? Canadian Sponsor Given Greenlight by Health Canada & FDA to Find Out

Publicly traded Appili Therapeutics out of Canada, a biotech venture attempting to commercialize Avigan® tablets (favipiravir), the antiviral drug originating from Japan that has been approved in Russia, Eastern Europe and on an emergency basis in India and China for...

Fujita Health University Favipiravir Trial Evidences no Statistically Conclusive Benefit to COVID-19 Patients: A Question Mark for Favipiravir?

Fujita Health University concluded a clinical study of the antiviral drug Avigan and report it has failed to demonstrate a clear efficacy in treating SARS-CoV-2 patients in the early stage of the infection. The Japanese university reports that the delta between those...

Pin It on Pinterest